Project Aim(s): This proposal aims to combine our novel EEG based technology with detailed neuropsychological assessment to provide a quantitative measure of cognitive change in MS that could be used in a clinical trial setting.  The study will also  provide an opportunity to assess for the first time the impact of Cladribine on cognitive performance using conventional screening tools, detailed neuropsychological batteries, and experimental neurophysiology based paradigms that could be harnessed for future nested case control studies.

Project Aim(s): TUDCA-ALS will focus on amyotrophic lateral sclerosis (ALS) a rare neurodegenerative disorder. TUDCA-ALS is based on the results of a successful proof-of-concept trial and has the ambition to develop a novel therapy in patients with ALS, based on administration of tauroursodeoxycholic acid (TUDCA) in addition to riluzole. TUDCA-ALS aims to perform a state-of-art randomized control trial on safety and efficacy of TUDCA in patients with sporadic ALS, without cognitive involvement and to exploit the project results into a novel therapeutic treatment for ALS.

Project Aim(s): To execute preclinical testing of an HDAC3-specific inhibitor for disease prevention in Huntington's disease (HD).

Project Aim(s): To develop and assess the feasibility of a theoretically-informed, evidence-based and sustainable intervention to rationalise antipsychotic prescribing in nursing home residents with dementia.

Increased knowledge about the pre-clinical and early clinical stages of Alzheimer's disease (AD) will be key in developing preventative strategies for the disease as well as development of therapeutic treatment strategies. In addition, this approach will contribute to the development of biomarkers for the early diagnosis of AD.